A retrospective real-world study strengthens evidence that early, sustained treatment with the antiamyloid lecanemab can slow the course of Alzheimer’s disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/real-world-data-support-lecanemab-early-ad-2025a1000y4o?src=rss
Author :
Publish date : 2025-12-05 13:07:00
Copyright for syndicated content belongs to the linked Source.
